Skip to content
value.today

CareDx, Inc: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Fewer than two of the last three years have both cash from operations and capital spending on file.

Price to salesPrice to sales of Diagnostics and Research: $874 M to $3.0 B, median $1.8 BPrice to bookPrice to book of Diagnostics and Research: $824 M to $4.2 B, median $1.9 B$0 M$1.1 B$2.3 B$3.4 B$4.6 BMarket value $3.4 B

Your own DCF model

A full discounted-cash-flow model of CareDx, Inc, started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Diagnostics and Research

Multiples of its companies with a market value at most 60 days old, times CareDx, Inc's own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)CareDx, IncApplied toValue (25th to 75th)Companies
Price to sales2.3× / 4.8× / 8.0×6.8×revenue $380 M$874 M to $3.0 B36
Price to book2.7× / 6.4× / 14.0×11.1×book equity $303 M$824 M to $4.2 B34

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

CareDx, Inc's multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

30.3×

Now above its median of 15.3×, in the top quarter of its range; range 11.5× to 30.3× over 12 months.

0×8×15×23×30×2026P/E 30×Median 15×

Price to sales

7.3×

Now above its median of 3.0×, in the top quarter of its range; range 1.9× to 43.7× over 28 months.

0×11×22×33×44×2020202120222023202420252026Price to sales 7×Median 3×

Price to book

11.1×

Now above its median of 2.9×, in the top quarter of its range; range 1.3× to 36.0× over 28 months.

0×9×18×27×36×2020202120222023202420252026Price to book 11×Median 3×

as of Oct 19, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 19, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$380 M$-21 M$42 M———SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$334 M$53 M$38 M———SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$280 M$-190 M$-18 M———SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$322 M$-77 M$-25 M———SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$296 M$-31 M$-19 M———SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$192 M$-19 M$33 M——$-135 MSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $3.4 B on Oct 19, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.